Zynerba Pharmaceuticals (ZYNE) Stock Climbs 6.7%; Rated Strong Buy

 

Zynerba Pharmaceuticals Inc (ZYNE) stock is up 6.7% Wednesday and higher by 15% over the last week. ZYNE stock is up 63.11% over the last 30 days and has risen 49.47% over the last 12 months. The average rating from Wall Street analysts is a Strong Buy. Stock Score Report, InvestorsObserver’s proprietary scoring system, gives ZYNE stock a score of 79 out of a possible 100.

That score is chiefly influenced by a long-term technical score of 100. ZYNE’s score also includes a short-term technical score of 93. The fundamental score for ZYNE is 44. In addition to the average rating from Wall Street analysts, ZYNE stock has a mean target price of $19.58. This means analysts expect the stock to climb 38.77% over the next 12 months.

Click Here to get the full Stock Score Report on Zynerba Pharmaceuticals Inc (ZYNE).

What’s Happening with ZYNE Stock Today

Zynerba Pharmaceuticals Inc (ZYNE) stock is higher by 6.73% while the S&P 500 has risen 0.76% as of 3:03 PM on Wednesday, May 15. ZYNE has risen $0.89 from the previous closing price of $13.22 on volume of 1,989,020 shares. Over the past year the S&P 500 has gained 4.61% while ZYNE has risen 49.47%. ZYNE lost -$2.27 per share in the over the last 12 months.

Symbols: ZYNE

You May Also Like